#remdesivir price

[sweetdreamspootypie]

My ward is the respiratory ward, so a good chunk of it is dedicated to caring for people experiencing exacerbations of COPD - that is, lung infections and inflammation spikes in people with lung disease which is usually (but not always) caused by a lifetime of smoking

And with the generation shift with smoking attitudes, maybe we will get to a time where that is not simply the fact of life for the older demographic. There will come a time when it's not just a given that everyone smoked and breathlessness and pneumonia will be the thing that will probably kill you eventually.

Except of course, the general population has been repeatedly exposed to COVID now and will continue to be.

So congrats I guess. The Youth now have a good chance of coming pre-installed with pneumonitis scarring on the lungs. Or getting post covid autoimmune diseases.

(young people are less likely to get pneumonitis that's true. But I I've seen stuff about drug companies hiking the price of remdesivir and paxlovid, so overall there is going to be an increase in more severe outcomes on average)

[please note I haven't researched shit for this post. This is stream of consciousness musing in response to the many posts I've seen recently about long covid]

[darkmaga-retard]

https://www.globalresearch.ca/national-blackout-affordable-healthcare/5865760

The National Blackout on Affordable Healthcare. “Undermine the Legitimacy of Universal Healthcare”

By Richard Gale and Dr. Gary Null

Global Research, August 20, 2024

As the last remaining months click down before the November elections, there has been a surreal national blackout about the dreadful state of Americans’ physical and mental health. It is the forbidden subject in Washington. A viable and affordable healthcare system is utterly taboo across the mainstream media networks, which receive their salaries from the pharmaceutical industry. Libertarians, in their infinite self-centered deregulatory non-wisdom, unsurprisingly ignore the subject altogether. Only Robert Kennedy Jr is determined to throw out the moneychangers in the federal health agencies, and Dr. Jill Stein remains committed to single payer universal health coverage. And for this reason, Washington concocts every imaginable obstacle in order to bar them from the election ballot.

The onslaught of misinformation from the corporatist wings of both political parties and media biases against universal healthcare are obviously confusing the electorate. This confusion leaves citizens bewildered about how they will pay their bills unless a fundamental overhaul of medical insurance is undertaken. More important, what will happen when you are diagnosed with a serious illness and are not fully covered? What are your chances of joining the ranks of the 530,000 families that file bankruptcy annually for medical reasons? Medical debt continues to be a growing crisis as the nation now spends $3.5 trillion annually; however. It rose to $4.3 trillion in 2021.  For 2023, Americans owed at least $220 billion in medical debt, with emergency room visit costs being the leading culprit. According to the American Journal of Public Health, 66.5% of bankruptcies are medically-related.  In the past, it was rare for people to go bankrupt because they did not have accessible medical care. There was a time in the US when medicine carried a higher standard of ethics. The Hippocratic Oath was respected and no one was denied medical care because they could not afford it.  But that was in the past. Obama’s Affordable Care Act, which the Democrat Party continues to believe is a successful piece of legislation, has over the years been shown to be a disaster and has only accomplished an increase in the financial burden on individuals and families. As a consequence, the quality of healthcare has also steadily declined.

During the course of the Covd-19 pandemic, personal medical debt burden rose for diagnostic testing and outrageously expensive and questionable treatments, including price gouging for novel anti-SARS-2 drugs such as Remdesivir and Paxlovid. 

The full throttle offensive launched by the insurance and medical industrial complex continues to undermine the legitimacy of universal healthcare. It has bought unbridled biased coverage across the media waves. The goal is to effectively sustain the current healthcare system in place. After listening to dozens of commentators on CNN, MSNBC, Fox, and the pseudo-health journalists at the New York Times, one would think that a socialized medical system is only offering free stuff at enormous cost to taxpayers. No one truly knows how much a national universal program would cost. Forecasts for a 10-year period range would be approximately $13 trillion at a bare minimum but still far less than the current annual expenditure rate of $3.5 trillion. It would be very expensive and for it to succeed dramatic infrastructural changes would need to be made throughout the entire medical establishment at both the private and public levels.  That conversation is long overdue.

[nitasonwane]

Global Small Molecule API Market 2023-2030

For a very long time, small molecule APIs have served as the pharmaceutical industry's mainstay. As they can largely be taken orally and can penetrate cellular membranes to reach intracellular targets, these products have specific therapeutic advantages. Pharmaceutical Technology article states that tiny molecules make up about 58% of the medicinal products now being developed. As chronic diseases are becoming increasingly common worldwide, pharmaceutical companies have been forced to provide more therapeutic pharmaceuticals as a result of the rising demand for these goods. Fortune Business Insights presents this information in their report titled "Global Small Molecule API Market, 2023–2030."

COVID-19 Impact:

Due to Supply Chain Restrictions during the Pandemic, the Market Grew More Slowly

The global pharmaceutical industry's dynamics were impacted by the COVID-19 pandemic. During COVID-19, the market appeared as both a challenge and an opportunity globally. Plant operations were impacted by the pandemic's severe supply chain and logistics disruptions. As a result, businesses experienced pricing pressure as the pandemic drove up the cost of these products. However, the pandemic increased the need for therapeutic pharmaceuticals to treat the SARS-CoV-2 virus, which led factories all over the world to produce more items such as Remdesivir, Favipiravir, and Itolizumab. Moreover, there was an upsurge in demand for the anti-infective and antipyretic medications used to treat COVID-19 symptoms, resulting in a favorable effect on the market growth.

Report Coverage: The report offers:  •    Major growth drivers, restraining factors, opportunities, and potential challenges for the market.  •    Comprehensive insights into the regional developments.  •    List of major small molecule APIs industry players.  •    Key strategies adopted by the market players.  •    Latest industry developments include product launches, partnerships, mergers, and acquisitions.

Competitive Landscape

Diversified Portfolios Assist Key Players to Maintain Dominance

The global Small Molecule API Market is fragmented. Top players, such as Lonza, EuroAPI, and Pfizer Inc., offer a wide variety of products. With a diversified portfolio, market leaders enjoy a commanding position. Its substantial market share is a result of companies equipped with cutting-edge technologies. Small and medium companies, along with large pharmaceutical companies, focus on initiating small molecule therapeutic agents in the market. Companies are operating to get regulatory approvals and establish significant market share.

[veritywarner90]

The biggest pedlars of misinformation in recent years have been;

ABC - Russian collusion hoax, Covid alarmism, Climate scare campaign

Department of Health - "safe & effective" lie, promoting paper & cloth masks as effective

TGA - promoting Remdesivir & Molnupiravir while banning Ivermectin

Bureau of Meteorology - fiddling with climate records to cool the past and warm the present.

The Federal Government - more renewables lowers electricity prices

Yet they are all excluded from the proposed legislation to combat "misinformation"

So the ABC, Nine, SMH, The Australian & The Guardian are all free to continue spewing out misinformation - but up & coming media like Rebel News, The Aussie Wire & Real Rukshan must comply with the diktats of the Ministry of Truth

https://t.co/CWVZUBvcOx

https://twitter.com/CKellyUAP/status/1673114788044636160

Read more articles at:

https://veritywarner90.wordpress.com

[worldspotlightnews]

ECC refuses to increase price of Remdesivir injection

Pharmacy employees wearing facemasks as a preventive measure against the coronavirus attend to customers in Islamabad, Pakistan, on March 23, 2020. — AFP The Economic Coordination Committee (ECC) of the federal cabinet Monday decided not to increase the price of Remdesivir injection, used for the treatment of COVID-19, Radio Pakistan reported. The ECC, under the chair of Finance Minister Ishaq…

[theyoungturks]

The Biden administration has decided not to take measures to lower the cost of an astronomically expensive cancer drug. John Iadarola, Cenk Uygur, and Emma Vigeland discuss on The Young Turks. Watch TYT LIVE on weekdays 6-8 pm ET. http://youtube.com/theyoungturks/live Read more HERE: https://www.levernews.com/biden-and-becerra-let-big-pharma-profiteer-off-cancer-drug/ "In the summer of 2020, then-California Attorney General Xavier Becerra demanded the Trump administration use existing law to lower the price of medicines that were originally developed at taxpayer expense. “We cannot afford to leave the supply of this critical medication to chance and the whims of the marketplace when it was funded in part by taxpayer dollars,” Becerra wrote in a letter to the Trump administration in response to the high price of Remdesivir, which treats COVID-19. Less than three years later, the agency run by Becerra — now Health and Human Services (HHS) Secretary in the Biden administration — just rejected the same demand from two cancer patients unable to afford the $180,000-a-year price of a medicine whose development was originally funded by the public." *** The largest online progressive news show in the world. Hosted by Cenk Uygur and Ana Kasparian. LIVE weekdays 6-8 pm ET. Help support our mission and get perks. Membership protects TYT's independence from corporate ownership and allows us to provide free live shows that speak truth to power for people around the world. See Perks: ▶ https://www.youtube.com/TheYoungTurks/join SUBSCRIBE on YOUTUBE: ☞ http://www.youtube.com/subscription_center?add_user=theyoungturks FACEBOOK: ☞ http://www.facebook.com/TheYoungTurks TWITTER: ☞ http://www.twitter.com/TheYoungTurks INSTAGRAM: ☞ http://www.instagram.com/TheYoungTurks TWITCH: ☞ http://www.twitch.com/tyt 👕 Merch: http://shoptyt.com ❤ Donate: http://www.tyt.com/go 🔗 Website: https://www.tyt.com 📱App: http://www.tyt.com/app 📬 Newsletters: https://www.tyt.com/newsletters/ If you want to watch more videos from TYT, consider subscribing to other channels in our network: The Watchlist https://www.youtube.com/watchlisttyt Indisputable with Dr. Rashad Richey https://www.youtube.com/indisputabletyt Unbossed with Nina Turner https://www.youtube.com/unbossedtyt The Damage Report ▶ https://www.youtube.com/thedamagereport TYT Sports ▶ https://www.youtube.com/tytsports The Conversation ▶ https://www.youtube.com/tytconversation Rebel HQ ▶ https://www.youtube.com/rebelhq TYT Investigates ▶ https://www.youtube.com/channel/UCwNJt9PYyN1uyw2XhNIQMMA #TYT #TheYoungTurks #BreakingNews 230324__TA05BigPharma by The Young Turks

[breaking-news-portal]

Got remdesivir from minister wife’s driver: arrested MP man

Got remdesivir from minister wife’s driver: arrested MP man

A man arrested for allegedly selling remdesivir in black market on Tuesday claimed that he had got the vials from a fellow driver who worked for Madhya Pradesh minister Tulsiram Silavat’s wife. After a video in which the accused, Punit Agarwal (27), purportedly made the claim went viral on social media, the minister on Wednesday denied any involvement of his family. Opposition Congress sought his…

[24x7newsbengal]

Remdesivir price reduced by manufacturers after several states report shortage of key drug

Remdesivir price reduced by manufacturers after several states report shortage of key drug

Image Source : FILE PHOTO/PTI Major manufacturers of Remdisivir have reduced the price considerably. (Photo for representation only) The demand for Remdesivir, an injectable medicine, has soared manifold amid skyrocketing coronavirus cases in the country. Amid reports of several states pressing the alarm button over the acute shortage of the key antiviral drug, manufacturers have now decided to…

[marathinewslive]

कोरोना रुग्णांना देण्यात येणाऱ्या Remdesivir बाबत मोदी सरकारचा मोठा निर्णय | Coronavirus-latest-news

कोरोना रुग्णांवरील उपचारात रेमडेसिवीर (Remdesivir) औषध प्रामुख्याने वापरलं जातं. मुंबई, 14 एप्रिल : गेले काही दिवस रेमडेसिवीर (Remdesivir) औषध बरेच चर्चेत आहे. कोरोना रुग्णांवर उपचारासाठी वापरल्या जाणाऱ्या या औषधाचा तुटवडा जाणवतो आहे, हे औषध वाढीव दराने विकलं जात आहे, या औषधाचा काळाबाजार केला जात आहे. अशा बऱ्याच बातम्या कानावर येत आहेत. दरम्यान आता याच औषधाबाबत मोदी सरकारने एक मोठा निर्णय घेतला…

[newshindiplus]

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग ने जताई आपत्ति

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग ने जताई आपत्ति

[ad_1]

एंटी-वायरल ड्रग्स रेमेडिसविर और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर आपत्ति जताई है. सरकारी सूत्रों ने CNBCTV-18 को बताया कि फार्मा विभाग ने एंटी-वायरल ड्रग्स रेमडेसिविर ((Anti-Viral Drugs Remdesivir) ) और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर…

[ddtvnews]

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग जताई आपत्ति

कोरोना की कारगर दवा रेमेडिसविर और टोसीलिज़ुमाब के ओवर प्रिसक्रिप्शन पर भारतीय फार्मा विभाग जताई आपत्ति

[ad_1]

एंटी-वायरल ड्रग्स रेमेडिसविर और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर आपत्ति जताई है. सरकारी सूत्रों ने CNBCTV-18 को बताया कि फार्मा विभाग ने एंटी-वायरल ड्रग्स रेमडेसिविर ((Anti-Viral Drugs Remdesivir) ) और टोसीलिज़ुमाब के ओवर-प्रिस्क्रिप्शन पर…

[lok-shakti]

तीस दिन में एक भी रेमडेसिविर की बिक्री नहीं, गोदामों में 73 लाख के इंजेक्शन डंप

तीस दिन में एक भी रेमडेसिविर की बिक्री नहीं, गोदामों में 73 लाख के इंजेक्शन डंप

प्रतीकात्मक तस्वीर। – फोटो : Social media ख़बर सुनें ख़बर सुनें कोरोना की दूसरी लहर में संक्रमितों के लिए संजीवनी माने गए रेमडेसिविर इंजेक्शन की बिक्री अब ठप है। बीते तीस दिनों में एक भी रेमडेसिविर इंजेक्शन की बिक्री नहीं हुई है। स्टाकिस्टों के गोदामों में करीब 73 लाख के इंजेक्शन डंप हैं। कंपनियां सौदे के मुताबिक इंजेक्शन की वापसी लेने को तैयार नहीं हैं। ऐसे में थोक दवा कारोबारियों को इंजेक्शनों…

[getmedsphilippines]

Getmeds.ph is the Philippines' leading online drugstore with a one-stop destination for healthcare products, such as over-the-counter pharmaceuticals, healthcare devices, prescriptions, bath and body, and personal care medicines.

[weelectronicstudentreviewstuff]

Remdesivir availability American biopharmaceutical company Gilead Remdesivir price in India

Remdesivir availability American biopharmaceutical company Gilead Remdesivir price in India

Image Source : AP IMAGE Gilead announces steps to expand Remdesivir availability in India American biopharmaceutical company Gilead has announced steps to expand the availability of remdesivir, a key therapeutic medicine used in the treatment of COVID-19 patients, in India. “The recent surge of COVID-19 cases in India is having a devastating impact on communities and has created unprecedented…

[journalistcafe]

सरकार ने घटाएँ दाम, अब सस्ते मे मिलेगी कोरोना की ये दावा

सरकार ने घटाएँ दाम, अब सस्ते मे मिलेगी कोरोना की ये दावा

  कोरोना ने जहां पुरे देश को डरा रखा है, वही उसके इलाज के लिए एक रहत की खबर आ रही है. कोरोना के गंभीर मरीजों के इलाज के लिए इस्तेमाल होने वाली Remdesivir के दामों मे काफी कमी आई है. इसे कंपनिया अभी तक 2800 से 5400 रुपये प्रति इंजेक्शन की एमआरपी पर बेच रहीं थीं, लेकिन अब ये कीमतें 899 से 3490 रुपये प्रति इंजेक्शन के बीच कर दी गई है। राष्ट्रीय औषध मूल्य प्राधिकरण (एनपीपीए) ने एक बयान जारी कर कहा…